Posted by Michael Wonder on 19 Dec 2022
Eagle Pharmaceuticals receives FDA approval for additional indication for Pemfexy in combination with pembrolizumab and platinum chemotherapy
19 December 2022 - Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small-cell lung cancer with no EGFR or ALK genomic tumour aberrations.
Eagle Pharmaceuticals announced today that the US FDA has approved an additional indication for Pemfexy (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small-cell lung cancer with no EGFR or ALK genomic tumour aberration.
